Trials / Completed
CompletedNCT00434291
Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia
A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 264 (estimated)
- Sponsor
- TaiGen Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety and efficacy of TG-873870(Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia(CAP)
Detailed description
Community-acquired Pneumonia(CAP) remains a leading cause of death in both developing and developed countries. In the choice of antibacterial agents used to treat CAP, fluoroquinolones have received considerable attention because of their wide spectrum of bactericidal activity. TG-873870(Nemonoxacin), a non-fluorinated quinolone (NFQ), is a selective bacterial topoisomerase inhibitor. This study will test the safety and efficacy of TG-873870(Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia (CAP) .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG-873870(Nemonoxacin) |
Timeline
- Start date
- 2006-12-01
- Completion
- 2007-08-01
- First posted
- 2007-02-13
- Last updated
- 2009-11-25
Locations
20 sites across 2 countries: South Africa, Taiwan
Source: ClinicalTrials.gov record NCT00434291. Inclusion in this directory is not an endorsement.